 Shares of Graphite Bio Inc. are set to start trading Friday, after the California-based gene-editing biotechnology companys upsized initial public offering priced at the top of the expected range. The company raised 238 million, as it said late Thursday that sold 14.0 million shares in its IPO, which priced at 17 a share. 